Chiu S.S.,Lawson Health Research Institute |
Majeed M.,Sabinsa Corporation |
Majeed M.,Sami Labs. Ltd. |
Vishwanatha J.K.,University of North Texas |
And 5 more authors.
Anticancer Research | Year: 2011
Background: The neuropathic side-effects of trauma, stroke or therapeutic radiation of the brain for life-threatening neoplastic diseases are the result of damage to normal tissues resulting in defects in cognition and memory. Based upon published preclinical data of curcumin activity application of parenteral curcumin formulations may prove to be to be promising chemotherapy for disorders following neuropathic insults. Studies in in vitro and animal models suggest curcumin may be an effective remediative agent for brain damage. The initial steps in curcumin development for clinical applications to neuropathic disorders are formulating it for intravenous administration, determining the formulated product passes the blood-brain barrier and reaches therapeutic amounts in damaged areas in the brain with tolerable safety. Following intravenous administration of liposomal curcumin, polymeric nanocurcumin and polylactic glycolic acid co-polymer (PLGA)-curcumin in rats, these formulations were observed to cross the blood-brain barrier using a sensitive HPLC assay. All three formulations localized in specific sites in the brain without observable adverse events. One hour following intravenous injection of 5 mg/kg nanocurcumin, or 20 mg/kg PLGA-curcumin, or liposomal curcumin, up to 0.5% of the injected material localized in the brain stem, the striatum, and the hippocampus with varied accumulation and clearance rates. Conclusion: These data indicate that curcumin does localize in putative damaged brain tissues and suggest therapeutic trials be explored with all three formulations in animal models with pre- and post traumatic states.
Yadav V.,Banaras Hindu University |
Chatterjee S.S.,Stettiner Strae 1 |
Majeed M.,Sami Labs Ltd |
Kumar V.,Banaras Hindu University
Journal of Traditional and Complementary Medicine | Year: 2015
Aim: To compare stress resistance increasing and analgesic activities of piperlongumine and a methanolic Piper longum fruit extract (PLE). Methods: Efficacies of a single and repeated daily oral doses (1-256 mg/kg/day) of PLE, piperlongumine, and 50 mg/kg/day doxycycline against foot shock stress triggered alteration in body weights and core temperatures, and of their 11 daily doses on antidepressants like activity in tail suspension test and on pentobarbital induced sedation in male mice were compared. In another experiment, analgesic activities of single and repeated daily 5 mg/kg oral doses of piperlongumine and PLE in mice hot plate test and in acetic acid induced writing tests were compared with those of aspirin and doxycycline. Results: After their single oral doses no effects of piperlongumine or PLE or doxycycline were observed in the footshock stress induced hyperthermia test or in hot plate test. However, significant effects of piperlongumine and PLE in both the tests were observed after their 5 or more daily doses. Both of them also dose dependently suppressed daily handling and repetitive testing triggered alterations in body weights and core temperatures. Their doxycycline like antidepressant activity in tail suspension test and aspirin like analgesic effects in acetic acid writhing test were observed after their 11 daily 5 mg/kg oral dose. Conclusion: Piperlongumine is another bioactive secondary metabolite of P. longum and other plants of piper species with stress response suppressing, analgesic, and anti-inflammatory activities. Its bactericidal activities can also contribute to its therapeutically interesting bio-activity profile. © 2015 Center for Food and Biomolecules, National Taiwan University.
Ramanujam R.,Sami Labs Ltd |
Ganjihal S.,Sami Labs Ltd |
Kalyanam N.,Sabinsa Corporation |
Majeed M.,Sabinsa Corporation
Tetrahedron Asymmetry | Year: 2013
The synthesis of chemically and enantiomerically pure (S)-3-amino tetrahydrofuran hydrochloride starting from the natural amino acids, l-aspartic acid or l-methionine is described. The process involves no chromatography and can be easily carried out on a large scale. The enantiopurity of the final product was established by NMR and chiral HPLC methods. © 2013 Elsevier Ltd. All rights reserved.
Majeed M.,Sami Labs Ltd |
Nagabhushanam K.,Sabinsa Corporation |
Natarajan S.,Sami Labs Ltd |
Vaidyanathan P.,Sami Labs Ltd |
Karri S.K.,ClinWorld Private Ltd
International Journal of Pharma and Bio Sciences | Year: 2014
Intra Ocular Pressure (IOP) is the fluid pressure inside the eye and is the most important risk factor for glaucoma. From the roots of Coleus forskohlii, an aromatic herb growing all over India, we extracted Forskolin. In this study we studied the IOP lowering activity of two strengths of Ocufors, viz., Ocufors® (Forskolin 1% w/v ophthalmic solution) and Ocufors® (Forskolin 0.15% w/v ophthalmic solution) in 12 New Zealand white rabbits, divided into three groups, four rabbits each. IOP was induced using water loading model in all three groups, as an acute model, with the right eye of all the animals received water for injection and thereby served as reference control. Whereas the left eye on all the three group animals received active drug, with Group 1 animals instilled with one drop of 1% w/v Forskolin solution while Group 2 and 3 animals instilled with one and two drops of 0.15% w/v Forskolin solution respectively. Post instillation of Forskolin 1% w/v ophthalmic solution (one drop), Forskolin 0.15% w/v ophthalmic solution, (one drop) and Forskolin 0.15% w/v ophthalmic solution (two drops) showed an IOP reduction of 23%, 19% and 30% at 45min, 45min and 75min respectively in New Zealand white rabbits, under test conditions employed. Forskolin aqueous clear ophthalmic solution showed a prolonged reducing effect on the IOP with one drop of 1% (w/v). However, a similar effect was noticed with two drops of 0.15% (w/v) Forskolin aqueous ophthalmic solution. Further clinical evaluation and confirmation of the low strength Ocufors (Forskolin 0.15% w/v) ophthalmic solution would help in replacing its higher strength counterpart (Forskolin 1% w/v) in mild open angle glaucoma patients.
Sami Labs Ltd | Date: 2012-10-17
The present invention relates to a composition containing peptide of SEQ ID No. 1 linked to oleanolic acid and a method of treating skin aging. The composition effectively reduces signs of ageing due to oxidation, collagen insufficiency and excess activity of serine proteases like elastase and collagenase that result in wrinkling of skin, fine expression lines, reduced skin thickness, hyperpigmentation, under eye dark circles, and premature ageing.
PubMed | National Taiwan University of Science and Technology, Sami Labs Ltd, Sabinsa Corporation, Rutgers University and National Kaohsiung Marine University
Type: Journal Article | Journal: Molecular nutrition & food research | Year: 2015
Diet-induced obesity and associated nonalcoholic fatty liver disease have increased and become a major health problem worldwide. This study was conducted to investigate the chemopreventive effects of dietary Calebin-A, a curcuminoid, on differentiation of 3T3-L1 adipocytes and high-fat diet (HFD) induced obesity and hepatic steatosis. Potential mechanisms contributing to these effects were also elucidated.Calebin-A effectively and dose dependently suppressed accumulation of lipid droplets in adipocytes through the suppression of adipogenic specific factor peroxisome proliferator-activated receptor (PPAR) and fatty acid synthase and activated acetyl-CoA carboxylase. Dietary Calebin-A effectively decreased weight gain and relative perigonadal, retroperitoneal, and mesenteric fat weight in HFD-fed mice. Furthermore, Calebin-A markedly reduced hepatic steatosis and the serum levels of glutamate oxaloacetate transaminase, glutamate pyruvate transaminase, total cholesterol, and triacylglycerol. These effects were associated with the downregulation of PPAR, sterol regulatory element-binding protein-1, and particularly the activation of AMP-activated protein kinase signaling found in both adipocytes and liver tissues.Taken together, these results demonstrated for the first time that Calebin-A suppressed adipocyte differentiation, prevented HFD-induced obesity, and improved hepatic steatosis, suggesting a novel application for the prevention and treatment of obesity and associated nonalcoholic fatty liver disease.
PubMed | Banaras Hindu University, Dr. Willmar Schwabe GmbH & Co. KG and Sami Labs Ltd
Type: Journal Article | Journal: Journal of intercultural ethnopharmacology | Year: 2015
To compare doxycycline (DOX) such as oral efficacies of piperlongumine (PL) and a Piper longum fruits extract (PLE) as stress resistance inducers.Efficacies of oral pretreatments with 5 mg/kg PL or PLE or of 50 mg/kg DOX for 10 consecutive days against stress resistance were compared. Mice in treated groups were subjected to a stress induced hyperthermia on the 1(st), 5(th), 7(th), and 10(th)day. Treated mice were then subjected to tail suspension test on the 11(th)day. Alteration in body weights, core temperatures, and gastric ulcers triggered by occasional exposures to foot shocks were determined.DOX like long-lasting protective effects of PL and PLE against gradual alterations in body weights, basal temperatures and transient hyperthermic responses triggered by foot shocks during the post-treatment days were observed. Altered responses of stressed mice in tail suspension test observed 1 day after the last foot-shock exposures and gastric ulcers and other pathologies quantified 1 day after the test were also suppressed in PL or PLE or DOX pretreated groups.PL and crude PLE are DOX like long-acting desensitizers of stress triggered co-morbidities. Reported observations add further experimental evidences justifying traditionally known medicinal uses of P. longum and other plants of the Piperaceae family, and reveal that PL is also another very long acting and orally active inducer of stress resistance. Efforts to confirm stress preventive potentials of low dose plant-derived products enriched in PL or piperine like amide alkaloids in volunteers and patients can be warranted.
PubMed | Sabinsa Corporation, FrieslandCampina Research and Sami Labs Ltd
Type: Journal Article | Journal: World journal of microbiology & biotechnology | Year: 2016
Commercial probiotics preparation containing Bacillus coagulans have been sold in the market for several decades. Due to its high intra-species genomic diversity, it is very likely that B. coagulans strain may alter in different ways over multiple years of production. Therefore, the present study focuses to evaluate the genetic consistency and probiotic potential of B. coagulans MTCC 5856. Phenotypic and genotypic techniques including biochemical profiling, 16S rRNA sequencing, GTG 5, BOX PCR fingerprinting, and Multi-Locus-Sequence typing (MLST) were carried out to evaluate the identity and consistency of the B. coagulans MTCC 5856. Further, in vitro probiotic potential, safety and stability at ambient temperature conditions of B. coagulans MTCC 5856 were evaluated. All the samples were identified as B. coagulans by biochemical profiling and 16S rRNA sequencing. GTG 5, BOX PCR fingerprints and MLST studies revealed that the same strain was present over 3years of commercial production. B. coagulans MTCC 5856 showed resistance to gastric acid, bile salt and exhibited antimicrobial activity in in-vitro studies. Additionally, B. coagulans MTCC 5856 was found to be non-mutagenic, non-cytotoxic, negative for enterotoxin genes and stable at ambient temperature (252C) for 36months. The data of the study verified that the same strain of B. coagulans MTCC 5856 was present in commercial preparation over multiple years of production.
PubMed | Sabinsa Corporation, ClinWorld Private Ltd and 19 1 & 19 2 and Sami Labs Ltd
Type: | Journal: Nutrition journal | Year: 2016
Bacillus coagulans MTCC 5856 has been marketed as a dietary ingredient, but its efficacy in diarrhea predominant irritable bowel syndrome (IBS) condition has not been clinically elucidated till date. Thus, a double blind placebo controlled multi-centered trial was planned to evaluate the safety and efficacy of B. coagulans MTCC 5856 in diarrhea predominant IBS patients.Thirty six newly diagnosed diarrhea predominant IBS patients were enrolled in three clinical centres. Along with standard care of treatment, 18 patients in group one received placebo while in group two 18 patients received B. coagulans MTCC 5856 tablet containing 2 10(9) cfu/day as active for 90 days. Clinical symptoms of IBS were considered as primary end point measures and were evaluated through questionnaires. The visual analog scale (VAS) was used for abdominal pain. Physicians global assessment and IBS quality of life were considered as secondary efficacy measures and were monitored through questionnaires.Laboratory parameters, anthropometric and vital signs were within the normal clinical range during the 90 days of supplementation in placebo and B. coagulans MTCC 5856 group. There was a significant decrease in the clinical symptoms like bloating, vomiting, diarrhea, abdominal pain and stool frequency in a patient group receiving B. coagulans MTCC 5856 when compared to placebo group (p < 0.01). Similarly, disease severity also decreased and the quality of life increased in the patient group receiving B. coagulans MTCC 5856 when compared to placebo group.The study concluded that the B. coagulans MTCC 5856 at a dose of 2 10(9) cfu/day along with standard care of treatment was found to be safe and effective in diarrhea predominant IBS patients for 90 days of supplementation. Hence, B. coagulans MTCC 5856 could be a potential agent in the management of diarrhea predominant IBS patients.
Sami Labs Ltd | Date: 2013-05-02
Dietary and nutritional supplements.